Navigation Links
Marrone Bio Innovations Announces Two New Executive Appointments
Date:12/11/2009

DAVIS, Calif., Dec. 11 /PRNewswire/ -- Marrone Bio Innovations (MBI) today announces 2 new additions to its executive management team. Mr. Chris Hildreth joined MBI as Senior Vice President of Commercial Operations, and is responsible for expanding all commercial aspects of the company, including sales, marketing, and business development functions. Dr. Kin Sing (Ray) Lam joined MBI as Vice President of Process Development, and leads the company's development efforts in scaling its broad pipeline of products to commercial manufacturing scale.

Chris Hildreth has extensive experience in the agricultural chemical industry, providing successful general management of sales organizations driven by profitable growth. Prior to arriving at MBI, he was Sr. Vice President and Director of Sales at AMVAC Corporation from 2003 to mid-2009. Before that, Hildreth held various sales and general management positions with United Agri Products, Inc., including Executive Vice President International, President and General Manager Distribution, President Products Company, United Agri Products Inc. and General Manager, UAP Canada.

"Chris is a highly accomplished and well-respected business manager and his extensive industry sales experience and complementary management style will be invaluable as he drives commercial growth at MBI," said Pam Marrone, Founder and CEO of Marrone Bio Innovations.

"I am very happy to be a part of the Marrone team," said Chris Hildreth. "Marrone Bio Innovations already has two efficacious products being sold commercially and an incredibly exciting pipeline. Natural products usage is increasing rapidly in both organic and standard crop production, as the efficacy of new products equals that of chemical products. The growth of natural product usage and Marrone Bio Innovations will be exceptional."

Dr. Ray Lam comes to MBI as an experienced and successful leader of multi-disciplinary teams of scientists in natural product discovery and development. He has a proven track record of advancing projects through developmental stages to industrial production. Prior to joining MBI, Ray was Vice President, Microbiology and Industrial Fermentation at Nereus Pharmaceuticals in San Diego, CA where he designed and developed the Marine Microbial Drug Discovery program. Before that, he was a Senior Principal Scientist in the Natural Products Department at Bristol-Myers Squibb Company in Connecticut.

"We are pleased to attract such a distinguished scientist and leader as Ray to lead our process development efforts," states Marrone. "With his extensive natural products experience, he will contribute scientifically to all of the company's R&D efforts from discovery through to commercial scale up."

Dr. Lam received his Ph.D. in Biochemistry from the University of Calgary, Calgary, Alberta, Canada and his M.A. and B.A. in Chemistry from the State University College of New York, Plattsburgh, New York. He is a long-standing member of several professional associations including the American Chemical Society, the American Society for Microbiology and the Society for Industrial Microbiology.

Marrone Bio Innovations (MBI) discovers, develops and markets effective and environmentally responsible products that fill unmet needs for weed, disease and pest management. MBI's effective and safe products come from a combination of in-licensed technology and its own discovery. The company's own R&D finds naturally occurring microorganisms from unique habitats and develops them into pest management products. MBI has an impressive pipeline of new products, including two insecticides, two herbicides and Zequanox(TM), a product for controlling invasive zebra and quagga mussels in fresh waterways. MBI currently markets Regalia® for control of fungal and bacterial diseases of both food and ornamental crops, and GreenMatch® Burndown Herbicide for weed control in organic crop production.

SOURCE Marrone Bio Innovations


'/>"/>
SOURCE Marrone Bio Innovations
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Marrone Bio Innovations Named an IC20 Company
2. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
3. Atrium Innovations Announces Management Changes
4. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
5. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
6. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
7. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
8. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
9. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
10. Inverness Medical Innovations Acquires ParadigmHealth
11. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Research and Markets has announced the addition of the "Cancer ... Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Cancer Biomarkers ... $15,737 million by 2022 from $6,521 in 2015, growing at a ... technologies segment accounted for more than half of the revenue share ...
(Date:1/19/2017)... 2017 /PRNewswire -- WuXi AppTec, a leading global ... technology platform, today announced that it has acquired ... drug discovery contract research organization (CRO). After completion ... subsidiary of WuXi, and will continue to focus ... services. The acquisition will further strengthen WuXi,s R&D ...
(Date:1/19/2017)... Berkeley, CA (PRWEB) , ... January 19, 2017 ... ... the delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers ... Mail is a fully 21 CFR Part 11-compliant email client designed to provide ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
Breaking Biology Technology:
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
(Date:12/7/2016)... December 7, 2016 According to a new market research ... Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - ... grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):